Recent

% | $
Quotes you view appear here for quick access.

Protalix BioTherapeutics, Inc. (PLX) Message Board

andre6677 8 posts  |  Last Activity: Feb 25, 2015 8:45 AM Member since: Feb 11, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    news

    by kontiki2015 Feb 25, 2015 8:41 AM
    andre6677 andre6677 Feb 25, 2015 8:45 AM Flag

    Thanks a lot
    Fantastic news

    Sentiment: Strong Buy

  • Reply to

    JMP UPGRADE !!!!

    by robertclark135 Jan 1, 2015 3:45 PM
    andre6677 andre6677 Jan 1, 2015 4:19 PM Flag

    December 2013 !!!!!!
    You are a fraud

  • ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia

    Sentiment: Strong Buy

  • ARIAD Pharmaceuticals, Inc. (ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded its review of Iclusig® (ponatinib) under the Article 20 referral procedure and has recommended that Iclusig continue to be used in Europe in accordance with its already approved indications.

    “We are grateful for the rigorous and in-depth review provided by the PRAC and the Scientific Advisory Group for Oncology,” stated Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “The PRAC recommendation provides insightful guidance to healthcare professionals and patients regarding the use of Iclusig in patients with Ph+ leukemias and importantly, leaves the original Iclusig indication statement unchanged. We look forward to consideration and adoption of these recommendations by the CHMP later this month and authorization by the European Commission by the end of the year.”

    The authorized indications of Iclusig in Europe, as approved in July 2013, are as follows:

    The treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation, or
    The treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
    Other recommendations made by the PRAC related to the Iclusig Summary of Medicinal Product Characteristics (SmPC) include, (1) patient monitoring for response according to standard clinical guidelines, (2) consideration of Iclusig dose-reduction following achievement of major cytogenetic response with subsequent monitoring of response and,

    Sentiment: Strong Buy

  • Reply to

    What is 50 day moving average for ARIA??

    by handsome868 Oct 7, 2014 8:33 AM
    andre6677 andre6677 Oct 7, 2014 8:37 AM Flag

    yesterday 5,82

  • Reply to

    EU PRAC

    by aaron_deepellum Oct 5, 2014 3:08 AM
    andre6677 andre6677 Oct 5, 2014 7:54 AM Flag

    It's not necessary I have found it and it's an old information (20/12/2013)
    It's manipulation

  • Reply to

    EU PRAC

    by aaron_deepellum Oct 5, 2014 3:08 AM
    andre6677 andre6677 Oct 5, 2014 7:52 AM Flag

    Old information !!!!!!! 20/12/2013 !!!!!

  • Reply to

    EU PRAC

    by aaron_deepellum Oct 5, 2014 3:08 AM
    andre6677 andre6677 Oct 5, 2014 7:49 AM Flag

    Thanks for these informations but could you give us a link ?

PLX
2.17-0.01(-0.46%)12:01 PMEDT